Skip to main content
SpringerLink
Log in

Pneumologie

  • Chapter
PET/CT-Atlas

  • 3297 Accesses

Zusammenfassung

Epidemiologie Weltweit werden jährlich 1,3 Mio. Neuerkrankungen verzeichnet, die Tendenz ist steigend [27]. Bei Männern macht das BC 22 % aller Karzinome aus, bei Frauen kommt es mit 8 % gleich hinter dem Mammakarzinom. Der Anteil des NSCLC (Non-Small Cell Lung Cancer, nichtkleinzelliges Bronchialkarzinom) beträgt 80 % an den Bronchialkarzinomen und 18 % an allen Karzinomen; das kleinzellige hält einen Anteil von ca. 20 %. Jährlich sterben 45 000 Menschen am Bronchialkarzinom, jeder 20. Mann in Deutschland ist betroffen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Al-Sugair A, Coleman RE (1998) Applications of PET in Lung Cancer. Semin Nucl Med 28: 303–319

    Article  PubMed  CAS  Google Scholar 

  2. Antoch G, Stattaus J, Nemat AT et al. (2003) Non-small cell lung cancer: Dual modality PET/CT in preoperative staging. Radiology 229: 526–533

    Article  PubMed  Google Scholar 

  3. Baldwin SA (1993) Mammalian passive glucose transporters: members of an ubiquitous familiy of active and passive transport proteins. Bioch Biophys Acta 1154: 17–49

    CAS  Google Scholar 

  4. Baum RP, Hellwig D, Mezzetti M (2004) Position of nuclear medicine modalities in the diagnostic workup of cancer patients: lung cancer. Q J Nucl Med Mol Imaging 48: 119–142

    PubMed  CAS  Google Scholar 

  5. Briele B, Willkomm P, Grünwald F et al. (1999) Darstellung sekundärer pulmonaler Veränderungen bei zentralen Bronchialkarzinomen in der F-18-FDG-PET. Nuklearmedizin 38: 323

    PubMed  CAS  Google Scholar 

  6. Brink I, Schumacher T, Mix M et al. (2004) Impact of [18F]FDG-PET on the primary staging of small cell lung cancer. Eur J Nucl Med Mol Imaging 31: 1614–1620

    Article  PubMed  CAS  Google Scholar 

  7. Czernin J (Guest Editor) (2007) PET/CT in cancer patient management. J Nucl Med: 1S–88S

    Google Scholar 

  8. Czernin J, Auerbach MA (2005) Clinical PET/CT imaging: Promises and misconceptions. Nuklearmedizin 44 (Suppl 1): S18–23

    Google Scholar 

  9. Czernin J, Weber W (2004) Translational molecular imaging. Molecular Imaging Biol 6: 183–187

    Article  Google Scholar 

  10. Czernin J, Allen-Auerbach M, Schelbert HR (2007) Improvements in cancer staging with PET/CT: Literature-based evidence as of September 2006. J Nucl Med 48 (Suppl 1): 78S–88S

    PubMed  CAS  Google Scholar 

  11. Dietlein M, Weber K, Grandjour A et al. (2000) Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany. Eur J Nucl Med 27: 1441–1456

    Article  PubMed  CAS  Google Scholar 

  12. Dietlein M, Moka D, Weber K et al (2001) Kosteneffektivität der PET im Behandlungsalgorithmus der Lungentumoren: Ein Vergleich gesundheitsökonomischer Daten. Nuklearmedizin 40: 122–128

    PubMed  CAS  Google Scholar 

  13. DKG (2008) Kurzgefasste interdisziplinäre Leitlinien 2008. Deutsche Krebsgesellschaft. http://www.krebsgesellschaft.de/wub_llkurz_2008,120883.html. Zugegriffen: 25. Januar 2010

  14. Erasmus JE, Page McAdams H, Connolly JE (2000) Solitary pulmonary nodules: Part II. Evaluation of the indeterminate nodule. Radiographics 20: 69–66

    Google Scholar 

  15. Erasmus JJ, Page Mc Adams H, Rossi SE, Goodman PC et al. (2000) FDG PET of pleural effusions in patients with non-small cell lung cancer. Am J Roentgenol 175: 245–249

    CAS  Google Scholar 

  16. Experts Multidisciplinary (2003) Thoracic disease site committee’s research strategy. http://www.acrin.org/lung_strategyhtml. Zugegriffen: 2006

  17. Farrel MA, McAdams HP, Herndon JE, Patz EF jr. (2000) Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease. Radiology 215: 886–890

    Google Scholar 

  18. Fowler J (2002) Nuclear medicine chemistry. J Nucl Med 42: 14N

    Google Scholar 

  19. Gambhir SS, Czernin J, Schwimmer J et al. (2001) A tabulated summary of the FDG PET Literature. J Nucl Med (Suppl) 42: 1–93

    Google Scholar 

  20. Gerbaudo VH, Sugarbaker DJ, Britz-Cunningham S et al. (2002) Assessment of malignant pleural mesothelioma with 18F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology. J Nucl Med 43: 1144–1149

    PubMed  Google Scholar 

  21. Goerres GW, von Schulthess GK, Steinert HC (2004) Why most PET of lung and head neck cancer will be PET/CT. J Nucl Med (Suppl 1) 45: 66S–71S

    PubMed  Google Scholar 

  22. Hammerschmidt S, Wirtz H (2009) Lungenkarzinom – aktuelle Diagnostik und Therapie. Dt Ärztebl 49: 809–818

    Google Scholar 

  23. Hauber HP, Bohuslavicki KH, Lund CH et al. (2001) Positron emission tomography in the staging of small cell lung cancer-a preliminary study. Chest 119: 950–954

    Article  PubMed  CAS  Google Scholar 

  24. Hicks RJ, Kalff V, MacManus MP et al. (2001) The utility of 18F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: Impact on management and prognostic stratification. J Nucl Med 42: 1605–1613

    PubMed  CAS  Google Scholar 

  25. Higashi K, Ueda Y, Ayabe K et al. (2000) FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Comm 21: 707–714

    Article  CAS  Google Scholar 

  26. Iagaru A, Chavla S, Menendez L, Conti P (2006) 18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas. Nucl Med Comm 27: 795

    Article  Google Scholar 

  27. Jemal A, Murray T, Ward E (2005) Cancer Statistics 2005. CA Cancer J Clin 55: 10–30

    Article  PubMed  Google Scholar 

  28. Kagna O, Solomonov A, Keidar Z et al. (2009) The value of FDGPET/ CT in assessing single pulmonary nodules in patients at high risk of lung cancer. Eur J Nucl Med Mol Imaging 36: 997

    Article  PubMed  Google Scholar 

  29. Keidar Z, Haim N, Guralnik L et al. (2004) PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med 45: 1640–1646

    PubMed  Google Scholar 

  30. Klett R, Röhrl A, Bauer R (2000) Nächtliche und belastungsbedingte pektanginöse Beschwerden durch vertebragene Dysfunktion. Herz/Kreislauf 32: 309–311

    Google Scholar 

  31. Knopp MV, Strauss LG, Dimitrakopoulou A et al. (1991) Positron emission tomography (PET ) in oncology – Its contribution for the diagnostic and therapeutic management of patients. In: Höfer R, Bergamnn H, Sinzinger H (Hrsg) Schattauer, Stuttgart, S 522–523

    Google Scholar 

  32. Krishnasetty V, Fischman AJ, Halpern EL, Aquino SL (2005) Comparison of alignment of computer-registered data sets: Combined PET/CT versus independent PET and CT of the thorax. Radiology 237: 635–639

    Article  PubMed  Google Scholar 

  33. Krüger S, Buck AK, Mottaghy FM et al. (2009) Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 36: 1807

    Article  PubMed  Google Scholar 

  34. Kubota K, Matsuzawa T, Fujiwara T et al (1990) Differential diagnosis of lung tumor with positron emission tomography: A prospective study. J Nucl Med 31: 1927–1933

    PubMed  CAS  Google Scholar 

  35. Lardinois D, Weder W, Hany TF et al. (2003) Staging of non-small cell lung cancer with integrated positron emission tomography and computed tomography. N Engl J Med 348: 2500–2507

    Article  PubMed  Google Scholar 

  36. Lee J, Aronchick JM, Alavi A (2001) Accuracy of F-18 fluordeoxyglucose positron emission tomography for the evalation of malignancy in patients presenting with new lung abnormalities. Chest 120: 1791–1797

    Article  PubMed  CAS  Google Scholar 

  37. Marom EM, Erasmus JE, Patz jr EF (2000) Lung cancer and positron emission tomography with fluorodeoxyglucose. Lung Cancer 28: 187–202

    Article  PubMed  CAS  Google Scholar 

  38. Marom EM, Sarvis S, Herndon JE et al. (2002) T1 lung cancers: Sensitivity of diagnosis with fluorodeoxyglucose PET. Radiology 223: 453–459

    Article  PubMed  Google Scholar 

  39. Nakamoto Y, Tatsumi M, Cohade C et al. (2003) Accuracy of image fusion of normal upper abdominal organs visualized with PET/ CT. Eur J Nucl Med Mol Imaging 30: 597–602

    Article  PubMed  Google Scholar 

  40. Ost D, Fein A (2000) Evaluation and management of the solitary pulmonary nodule. Am J Respir Crit Care Med 162: 782–787

    PubMed  CAS  Google Scholar 

  41. van Overhage H, Broekel K, Heijenbrok MW et al. (2004) Metastases in supraclavicular lymphnodes in lung cancer: Assessment with palpation, US and CT. Radiology 232: 75–80

    Article  Google Scholar 

  42. Pandit N, Gonen M, Krug L, Larson SM (2003) Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging 30: 78–84

    Article  PubMed  Google Scholar 

  43. Pauls S, Buck AK, Hohl K et al. (2007) Improved non-invasive T-staging in non-small cell lung cancer by integrated 18F-FDG PET/CT. Nuklearmedizin 46: 9–14

    PubMed  CAS  Google Scholar 

  44. Pieterman RM, van Putten JWG, Meuzelaar JJ et al. (2000) Preoperative staging of non-small-cell lung cancer with Positron-Emission-Tomography. N Engl J Med 343: 245–261

    Article  Google Scholar 

  45. Reske S, Kotzerke J (2001) FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, »Onko-PET III«, 21 July and 19 September 2000. Eur J Nucl Med 28: 1707– 1723

    Article  PubMed  CAS  Google Scholar 

  46. Rösch F (2004) Radionuklid-Generatorsysteme für die PET. Der Nuklearmediziner 27: 226–235

    Article  Google Scholar 

  47. Schaffler GJ, Wolf G, Schoellnast H et al. (2004) Non-small cell lung cancer: Evaluation of pleural abnormalities on CT scans with 18F FDG PET. Radiology 231: 858–865

    Article  PubMed  Google Scholar 

  48. von Schulthess GK (2004) Maximizing the benefit of integrated PET/CT: the road ahead. Eur J Nucl Med Mol Imaging 31: 1462– 1463

    Article  Google Scholar 

  49. Skoura EV, Exarhos D, Skilakaki M et al. (2009) Contribution of 18F-PET/CT in the management of patients with bronchioalveolar carcinoma (BAC): work in progress. Eur J Nucl Med Mol Imaging, Abstracts Ann Congr EANM 2009: P118, S333

    Google Scholar 

  50. Soriano Castrejon A, Garcia Vicente AM, Talavera Rubio MP et al. (2008) (18)F-FDG PET/CT respiratory gating of pulmonary lesions with low uptake: approximations towards clinical indicatins (Abstr). Nuklearmedizin 48: A145

    Google Scholar 

  51. Steinert HC (2004) PET und PET/CT beim Lungenkarzinom. Der Nuklearmediziner 27: 278–287

    Article  Google Scholar 

  52. Thibault H, Derumeaux G (2008) Assessment of myocardial ischemia and viability using tissue Doppler and deformation imaging:the lessons from the experimental studies. Arch Cardiovasc Dis 101(1): 61

    Article  PubMed  CAS  Google Scholar 

  53. Thie JA (2004) Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 45: 1431–1434

    PubMed  Google Scholar 

  54. van Tinteren H, Hoekstra OS, Smit EF et al. (2002) Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non small cell lung cancer: The PLUS multicentre randomized trial. Lancet 359: 1388–1392

    Article  PubMed  Google Scholar 

  55. Vahlensieck M (2000) Der pulmonale Rundherd – Dignitätsbeurteilung durch CT. Dt Ärztebl 97: C1871

    Google Scholar 

  56. Vansteenkiste JF, Mortelsman LA (1999) FDG-PET in the locoregional lymphnode staging of non-small cell lung cancer: a comprehensive review of the Leuven lung cancer group experience. Clin Pos Imag 2: 223–231

    Article  Google Scholar 

  57. Wahl A, Buck AK, Mueller A et al. (2004) CT, PET and PET/CT image fusion for the evaluation of suspicious pulmonary nodules and for staging NSCLC (Abstr. 10). Eur J Nucl Med Mol Imaging (Suppl 2) 31: S204–S205

    Google Scholar 

  58. Wahl RL (2004) Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT. J Nucl Med (Suppl 1) 45: 82S–95S

    PubMed  Google Scholar 

  59. Weber W, Dietlein M, Hellwig D, Kirsch C, Schicha H, Schwaiger M (2003) PET with 18F-fluordeoxyglucose for staging of non-smallcell lung cancer: Evidence-based recommendations and cost-effectivness. Nuklearmedizin 46: S135–S144

    Google Scholar 

  60. Wester HJ (2004) Entwicklung von PET-Tracern zur in-vivo-Charakterisierung der Tumorbiologie. Der Nuklearmediziner 27: 218–225

    Article  Google Scholar 

  61. Yi CA, Lee KS, Kim BT et al. (2006) Tissue characterization of solitary pulmonary nodule: Comparative study between helical dynamic CT and integrated PET/CT. J Nucl Med 47: 443

    PubMed  Google Scholar 

  62. Zhao DS, Valdivia AY, Li Y, Blaufox MD (2002) 18F-fluorodeoxyglucose positron emission tomography in small-cell lung cancer. Semin Nucl Med 32: 272–275

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diagnostisch Therapeutisches Zentrum, Kadiner Straße 23, 10243, Berlin

    Prof. Dr. med. Wolfgang Mohnike

  2. Kuckucksweg 25, 61462, Königstein

    Prof. Dr. med. Gustav Hör

  3. UCLA Molecular & Medical Pharmacology, 956948, 90095-6948, B2-085J CHS, Los Angeles, USA

    Prof. Dr. med. Heinrich Schelbert

Authors
  1. Prof. Dr. med. Wolfgang Mohnike
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Gustav Hör
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. med. Heinrich Schelbert
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Mohnike, W., Hör, G., Schelbert, H. (2011). Pneumologie. In: PET/CT-Atlas. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-17805-4_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-17805-4_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-17804-7

  • Online ISBN: 978-3-642-17805-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation